Form 4: Dianthus Therapeutics Director Jonathan Violin Acquires Stock Options
SEC Form 4 Filing
Director Jonathan Violin acquired 12,500 stock options in Dianthus Therapeutics on May 22, 2025.
Summary
- On May 22, 2025, Jonathan Violin, a director of Dianthus Therapeutics, acquired 12,500 stock options.
- The exercise price of these options is $18.36.
- The options vest on the earlier of the first anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service.
- The options expire on May 22, 2035.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting a standard stock option grant to a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It is a routine part of corporate governance and transparency.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/22/2025 | Date of transaction: Jonathan Violin acquired stock options. |
| 05/22/2025 | Date of signature. |
| 2026 Annual Meeting of Stockholders | Potential vesting date of stock options. |
| 05/22/2035 | Expiration date of stock options. |
Keywords
stock options, Dianthus Therapeutics, director, Jonathan Violin, Form 4, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.